Merck aims for male Gardasil.
D000293:Adolescent; D000328:Adult; D052685:Alphapapillomavirus / Q000276:immunology*; D002648:Child; D017277:Drug Approval; D004345:Drug Industry / Q000639:trends; D005834:Genital Neoplasms, Male / Q000188:drug therapy / Q000517:prevention & control*; D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D006801:Humans; D008297:Male; D030361:Papillomavirus Infections / Q000517:prevention & control*; D053918:Papillomavirus Vaccines / Q000191:economics; D015229:Sexually Transmitted Diseases, Viral / Q000188:drug therapy / Q000517:prevention & control*; D055815:Young Adult
D000068857:Human Papillomavirus Recombinant Vaccine Quadrivalent, Types 6, 11, 16, 18; D053918:Papillomavirus Vaccines